Empo Health, founded in 2020, develops technology for remotely monitoring diabetic foot health. The company aims to prevent complications such as ulcers and amputations, addressing a condition that leads to approximately 150,000 lower-extremity amputations annually in the United States. Its founders were trained at MIT and Stanford.
The company's primary product is the Empo Footprint imaging scale, an FDA-listed device that captures high-resolution images of patients' feet for diabetic neuropathy monitoring. It is paired with the Empo Remote Health Link, a HIPAA-compliant service that automatically transmits these images from patients' homes to their care teams.
In pilot studies, the system reported near-daily patient engagement and detected early ulcer indications in half of participants. The company has secured $15 million in funding and focuses on remote patient monitoring and medical imaging, including image analysis for ulcer detection.
